Generic Medicine Info
Indications and Dosage
Anaemia in chemotherapy patients
Adult: 50-150 mg weekly.

Anabolic after debilitating illness, Postmenopausal osteoporosis, Metastatic breast cancer
Adult: As nandrolone decanoate: 25-100 mg once every 3-4 weeks.

Anaemia of chronic renal failure
Adult: As nandrolone decanoate: Female: 50-100 mg once weekly. Male: 100-200 mg once weekly. Discontinue if there is no improvement within 3-6 months.
Prostatic or breast carcinoma (male); nephrosis, porphyria; infants, pregnancy and lactation.
Special Precautions
Monitor diabetic patients carefully. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Hepatic impairment. Elderly. Discontinue if signs of virilisation in women occur. Monitor skeletal maturation in children.
Adverse Reactions
Male: Postpubertal: Acne, gynaecomastia, bladder irritability, priapism, insomnia, chills, decreased libido, hepatic dysfunction, nausea, diarrhoea, prostatic hyperplasia. Prepubertal: Acne, virilism, chills, insomnia, hyperpigmentation, diarrhoea, nausea. Female: Virilism, hypercalcaemia, nausea, diarrhoea, chills, insomnia, iron deficiency anaemia, hepatic dysfunction.
IM/Parenteral: X
Drug Interactions
May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).
Lab Interference
May alter glucose tolerance tests.
Description: Nandrolone is an anabolic steroid. It promotes tissue-building processes and protein anabolism. It also stimulates erythropoeitin production, causing an increase in haemoglobin and RBC volume.
Onset: 3-6 mth.
Duration: Up to 30 days.
Absorption: 77% (IM).
Metabolism: Hepatic.
Excretion: Via urine.
MIMS Class
Anabolic Agents
Disclaimer: This information is independently developed by MIMS based on Nandrolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
  • Deca-Durabolin
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Already a member? Sign in